32 C.F.R. Appendix B to Part 627—Resource List for Immunoprophylaxis of Personnel at Risk
Title 32 - National Defense
Title 32: National Defense
PART 627—THE BIOLOGICAL DEFENSE SAFETY PROGRAM, TECHNICAL SAFETY REQUIREMENTS (DA PAMPHLET 385–69)
Subpart H—Engineering Controls
Appendix B to Part 627—Resource List for Immunoprophylaxis of Personnel at Risk
B-1. Recommendations for Immunoprophylaxis of Personnel at Risk---------------------------------------------------------------------------------------------------------------- Description of disease Product Recommended for use in Source of product----------------------------------------------------------------------------------------------------------------Anthrax.......................... Inactivated vaccine. Personnel working regularly with USAMRIID.\1\ cultures, diagnostic materials, or infected animals.Botulism......................... Pentavalent toxoid Personnel working regularly with CDC.\3\ (A,B,C,D,E) cultures or toxin. (IND).\2\.Cholera.......................... Inactivated vaccine. Personnel working regularly with Commercially large volumes or high available. concentrations of infectious materials.Diphtheria Tetanus (Adult)....... Combined toxoid..... All laboratory and animal care Commercially personnel irrespective of agents available. handled.Eastern equine encephalitis (EEE) Inactivated vaccine Personnel who work directly and USAMRIID.\1\ (IND) \2\. regularly with EEE in the laboratory.Hepatitis A...................... Immune Serum Animal care personnel working Commercially Globulin [ISG directly with chimpanzees available. (Human)]. naturally or experimentally infected with Hepatitis A virus.Hepatitis B...................... Serum-derived or Personnel working regularly with Commercially recombinant vaccine. human blood and blood components. available.Influenza........................ Inactivated vaccine. (Vaccines prepared from earlier Commercially isolated strains may be of little available. value in personnel working with recent isolates from humans or animals).Japanese Encephalitis............ Inactivated vaccine Personnel who work directly and CDC.\3\ (IND) \2\. regularly with JE virus in the laboratory.Measles.......................... Live attenuated Measles-susceptible personnel Commercially virus vaccine. working with the agent or available. potentially infectious clinical materials.Meningococcal Meningitis......... Purified Personnel working regularly with Commercially polysaccharide large volumes or high available. vaccine. concentrations of infectious materials (does not protect against infection with group B meningococcus).Plague........................... Inactivated vaccine. Personnel working regularly with Commercially cultures of Yersinia pestis or available. infected rodents or fleas.Poliomyelitis.................... Inactivated (IPV) Polio-susceptible personnel Commercially and live attenuated working with the virus or available. (OPV) vaccines. entering laboratories or animal rooms where the virus is in use.Pox viruses (Vaccinia, Cowpox, or Live (lyophilized) Personnel working with orthopox CDC.\3\ Monkey Pox viruses). vaccinia virus. viruses transmissible to humans, with animals infected with these agents, and persons entering areas where these viruses are in use.Q Fever (Phase II) vaccine....... Inactivated (IND) Personnel who have no demonstrable USAMRIID.\1\ \2\. sensitivity to Q fever antigen and who are at high risk of exposure to infectious materials or animals.Rabies........................... Human diploid line Personnel working with all strains Commercially cell inactivated of rabies virus, with infected available. vaccine. animals, or persons entering areas where these activities are conducted.Rift Valley Fever................ Inactivated virus All laboratory and animal care USAMRIID.\1\ vaccine (IND) \2\. personnel working with the agent or infected animals and all personnel entering laboratories or animal rooms when the agent is in use.Rubella.......................... Live attenuated Rubella-susceptible personnel, Commercially virus vaccine. especially women, working with available. ``wild'' strains or in areas where these viruses are in use.Tuberculosis..................... Live, attenuated BCG vaccine ordinarily is not used Commercially (BCG) bacterial in laboratory personnel in the available. vaccine. U.S.Tularemia........................ Live attenuated Personnel working regularly with USAMRIID.\1\ bacterial vaccine cultures or infected animals or (IND).\2\. persons entering areas where the agent of infected animals are in use.Typhoid.......................... Inactivated vaccine. Personnel who have no demonstrated Commercially sensitivity to the vaccine and available. who work regularly with cultures.Venezuelan equine (VEE) Live attenuated Personnel working with VEE and the USAMRIID.\1\ encephalitis. (TC83) viral Equine Cabassou, Everglades, vaccine (IND).\2\. Mucambo, and Tonate viruses, or who enter areas where these viruses are in use.Western equine encephalitis (WEE) Inactivated vaccine Personnel who work directly and USAMRIID.\1\ (IND) \2\ with WEE regularly in the laboratory. virus.Yellow Fever..................... Live attenuated Personnel working with virulent Commercially (17D) virus vaccine. and avirulent strains of Yellow available. Fever virus.----------------------------------------------------------------------------------------------------------------\1\ For information, contact: United States Army Medical Materiel Development Activity, Fort Detrick, Frederick, MD 21701, telephone: (301) 663-7661.\2\ Investigational New Drug (IND).\3\ Clinical Medicine Branch, Division of Host Factors, Center for Infectious Disease, Centers for Disease Control, Atlanta, GA 30333, telephone: (404) 639-3356.Source: Adapted from recommendations of the PHS Immunization Practices Advisory Committee and Biosafety in Microbiological and Biomedical Laboratories.
Browse Previous |
Browse Next
